Explore & Learn

Dedicated to providing the highest quality to healthcare professionals world wide, we offer safe, efficient and convenient blood processing systems and technology solutions to meet the individual needs of your patients and donors.


The Amicus System for ECP has obtained CE mark approval for the indication of CTCL in the palliative treatment of the skin manifestations of cutaneous T-cell lymphoma (CTCL) that is unresponsive to other forms of treatment.

The Amicus ECP System is CE marked in compliance with the applicable requirements of the Medical Device Regulation (EU) 2017/745 and includes:

  • Amicus Separator
  • Phelix Photoactivation Device
  • Amicus ECP Apheresis Kits

ECP is not cleared for market in the US.

Not all products listed or shown are approved for sale, or available in all countries. Contact your local Fresenius Kabi Representative for additional information and product availability.

Refer to the product operator’s manual, instructions for use, and other associated labeling and information for a complete list of warnings, cautions, contraindications, and other pertinent information associated with the use of the products listed on this site.